News & Media
Apr 09 / 2021
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Hemostemix Announces a $2,500,000 Lead Order and its Clinical Trial and Litigation Updates
Apr 08 / 2021
Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.
Hemostemix Announces it is Trading on the Frankfurt Stock Exchange and it has Retained HE Capital Markets Ltd.
Jan 22 / 2021
HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
HEMOSTEMIX ANNOUNCES THE BREAD CONTRACT WITH THE DEPARTMENT OF FOREIGN AFFAIRS, TRADE & DEVELOPMENT CANADA
Dec 18 / 2020
HEMOSTEMIX ANNOUNCES CLOSING OF EXISTING PRIVATE PLACEMENT AND ANNOUNCES A NEW PRIVATE PLACEMENT
HEMOSTEMIX ANNOUNCES CLOSING OF EXISTING PRIVATE PLACEMENT AND ANNOUNCES A NEW PRIVATE PLACEMENT
Nov 27 / 2020
Hemostemix Announces Possession of All Clinical Trial Data and $2,500,000 Unit Financing
Hemostemix Announces Possession of All Clinical Trial Data and $2,500,000 Unit Financing
Jul 03 / 2020
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Hemostemix Filed an Injunction Against Accudata Solutions, Inc. for the Return of its Clinical Trial Midpoint Report and Data
Jun 19 / 2020
Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Hemostemix Announces $700,000 Non Broker Private Placement, Update on its Proceedings against Aspire Health Science, LLC
Jun 16 / 2020
HEMOSTEMIX ANNOUNCES DELAY IN FILING OF ANNUAL FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER
HEMOSTEMIX ANNOUNCES DELAY IN FILING OF ANNUAL FINANCIAL STATEMENTS AND APPLICATION FOR MANAGEMENT CEASE TRADE ORDER
Feb 19 / 2020
HEMOSTEMIX ANNOUNCES FINANCING UPDATE AND SECURED CONVERTIBLE DEBENTURE FINANCING OF UP TO $2,000,000
HEMOSTEMIX ANNOUNCES FINANCING UPDATE AND SECURED CONVERTIBLE DEBENTURE FINANCING OF UP TO $2,000,000
Feb 10 / 2020
HEMOSTEMIX ANNOUNCES THE APPOINTMENT OF DR. RONNIE HERSHMAN TO THE BOARD OF DIRECTORS AND PROVIDES A CORPORATE UPDATE
HEMOSTEMIX ANNOUNCES THE APPOINTMENT OF DR. RONNIE HERSHMAN TO THE BOARD OF DIRECTORS AND PROVIDES A CORPORATE UPDATE
Jan 17 / 2020
HEMOSTEMIX ADDS THE 20th ACTIVE CLINICAL TRIAL SITE AND ENROLLS THE 56TH TRIAL SUBJECT
HEMOSTEMIX ADDS THE 20th ACTIVE CLINICAL TRIAL SITE AND ENROLLS THE 56TH TRIAL SUBJECT
Dec 02 / 2019
Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting
Hemostemix Announces Appointment of Director and Postponement of Annual and Special Meeting
Oct 21 / 2019
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
Hemostemix Announces Positive Results and Conclusions Reported in Phase II CLI Trial Abstract
Jul 02 / 2019
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
Hemostemix Announces Ongoing Phase II CLI Trial Abstract Accepted for Presentation by Canadian Society for Vascular Surgery
Jun 27 / 2019
Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Apr 10 / 2019
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Hemostemix Announces Enrollment Milestone in the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
Feb 25 / 2019
Hemostemix announces UC Davis Health added as a trial site for Phase II Clinical Trial
Hemostemix announces UC Davis Health added as a trial site for Phase II Clinical Trial
Dec 20 / 2017
Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
Hemostemix Receives Health Canada Clearance to Continue with Critical Limb Ischemia Clinical Trials
Aug 17 / 2017
Hemostemix Inc. Announces Agreement to Resolve all Outstanding Matters with Hemostemix (Asia) Corporation (HEMA)
Hemostemix Inc. Announces Agreement to Resolve all Outstanding Matters with Hemostemix (Asia) Corporation (HEMA)
Jun 09 / 2017
Hemostemix Inc. Announces Update on Status of Agreement with Hemostemix (Asia) Corporation (HEMA)
Hemostemix Inc. Announces Update on Status of Agreement with Hemostemix (Asia) Corporation (HEMA)
Oct 03 / 2016
Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
Hemostemix Announces it has been Granted two Additional Patents in the US and in Canada
Sep 21 / 2016
Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility
Hemostemix Announces Successful Re-Certification of its Israeli Manufacturing Facility
Sep 01 / 2016
Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
Jan 21 / 2016
Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program
Hemostemix Company Information Now Available Through S&P Capital IQ Corporation Records Program
Dec 22 / 2015
Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
Hemostemix Poised to Expand Phase-2 Clinical Trial of Lead Product ACP-01 to the United States
Aug 10 / 2015
Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States
Hemostemix Receives FDA Clearance for Phase-2 Clinical Trial of Lead Product ACP-01 in the United States
Jul 27 / 2015
Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia
Hemostemix Enrolls 20th Participant and Treats 15th in International Clinical Trial for Critical Limb Ischemia
Jun 15 / 2015
Hemostemix to Present in Italy at the 2015 Gordon Research Conference on Assisted Circulation
Hemostemix to Present in Italy at the 2015 Gordon Research Conference on Assisted Circulation
Apr 20 / 2015
Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
Hemostemix to Present at the 2015 Annual Meeting of the Clinical Trials Association in Israel
Feb 02 / 2015
Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations
Hemostemix Names Dr. Hardean E. Achneck as Vice President of Clinical Research and Operations
Jan 28 / 2015
Hemostemix Names Gerald D. Brennan Jr. to Board of Directors; Announces Management Title Change
Hemostemix Names Gerald D. Brennan Jr. to Board of Directors; Announces Management Title Change